Quick Answer
TherapeuticsMD, Inc. reported Cash and Equivalents of $5.06 million for fiscal year 2024.
TherapeuticsMD, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $5.06M | +16.9% |
| 2023 | $4.33M | +3322.7% |
| 2011 | $126.4K | -70.1% |
| 2010 | $422.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $5.75M | — | +13.6% |
| December 31, 2024 | $5.06M | — | +3179.8% |
| September 30, 2012 | $154.2K | +0.2% | -88.4% |
| June 30, 2012 | $1.33M | +1595.8% | +579.9% |
| March 31, 2012 | $195.2K | +953.1% | +54.4% |
| December 31, 2011 | $126.4K | -70.1% | -17.9% |
| September 30, 2011 | $153.9K | +542.9% | +96.7% |
| June 30, 2011 | $78.3K | — | +322.2% |
- TherapeuticsMD, Inc. showed an increase of +16.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2024 period, TherapeuticsMD, Inc.’s cash and equivalents has grown by 1096.2% (from $422.9 thousand to $5.06 million).
- The most recent figure is from TherapeuticsMD, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: